Immunological and biological dissection of normal and tumoral salivary glands

References

• Zaura E, Brandt BW, Prodan A, et al. On the ecosystemic network of saliva in healthy young adults. Isme J. 2017;11(5):1218–1231. doi:10.1038/ismej.2016.199.
   PubMed Web of Science ®Google Scholar
• Lynge Pedersen AM, Belstrom D. The role of natural salivary defences in maintaining a healthy oral microbiota. J Dent. 2019;80 Suppl 1:S3–S12. doi:10.1016/j.jdent.2018.08.010.
   PubMed Web of Science ®Google Scholar
• La Rosa GRM, Gattuso G, Pedullà E, Rapisarda E, Nicolosi D, Salmeri M. Association of oral dysbiosis with oral cancer development. Oncol Lett. 2020;19(4):3045–3058. doi:10.3892/ol.2020.11441.[InsertedFromOnline]
   PubMed Web of Science ®Google Scholar
• Rai AK, Panda M, Das AK, et al. Dysbiosis of salivary microbiome and cytokines influence oral squamous cell carcinoma through inflammation. Arch Microbiol. 2021;203(1):137–152. doi:10.1007/s00203-020-02011-w.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay I, Verma M, Panda M. Role of Oral Microbiome Signatures in Diagnosis and Prognosis of Oral Cancer. Technol Cancer Res Treat. 2019;18:1533033819867354. doi:10.1177/1533033819867354.
   Web of Science ®Google Scholar
• Porcheri C, Mitsiadis TA. Physiology, Pathology and Regeneration of Salivary Glands. Cells. 2019;8(9)
   PubMed Web of Science ®Google Scholar
• Bradley PJ. Classification of Salivary Gland Neoplasms. Adv Otorhinolaryngol. 2016;78:1–8. doi:10.1159/000442119.[InsertedFromOnline]
   PubMedGoogle Scholar
• Fábián TK, Fejérdy P, Nguyen MT, Soti C, Csermely P. Potential immunological functions of salivary Hsp70 in mucosal and periodontal defense mechanisms. Arch Immunol Ther Exp (Warsz)). 2007;55(2):91–98. doi:10.1007/s00005-007-0012-z.[InsertedFromOnline]
   PubMed Web of Science ®Google Scholar
• Fábián TK, Hermann P, Beck A, Fejérdy P, Fábián G. Salivary defense proteins: their network and role in innate and acquired oral immunity. Int J Mol Sci. 2012;13(4):4295–4320. doi:10.3390/ijms13044295.
   PubMed Web of Science ®Google Scholar
• Ando T, Hatsushika K, Wako M, et al. Orally administered TGF-beta is biologically active in the intestinal mucosa and enhances oral tolerance. J Allergy Clin Immunol. 2007;120(4):916–923. doi:10.1016/j.jaci.2007.05.023.
   PubMed Web of Science ®Google Scholar
• Penttila I. Effects of transforming growth factor-beta and formula feeding on systemic immune responses to dietary beta-lactoglobulin in allergy-prone rats. Pediatr Res. 2006;59(5):650–655. doi:10.1203/01.pdr.0000203149.75465.74.
   PubMed Web of Science ®Google Scholar
• Mega J, McGhee JR, Kiyono H. Cytokine- and Ig-producing T cells in mucosal effector tissues: analysis of IL-5- and IFN-gamma-producing T cells, T cell receptor expression, and IgA plasma cells from mouse salivary gland-associated tissues. J Immunol. 1992;148(7):2030–2039.
   PubMed Web of Science ®Google Scholar
• Hofmann M, Pircher H. E-cadherin promotes accumulation of a unique memory CD8 T-cell population in murine salivary glands. Proc Natl Acad Sci U S A. 2011;108(40):16741–16746. doi:10.1073/pnas.1107200108.
   PubMed Web of Science ®Google Scholar
• Thom JT, Weber TC, Walton SM, Torti N, Oxenius A. The salivary gland acts as a sink for tissue-resident memory CD8(+) T cells, facilitating protection from local cytomegalovirus infection. Cell Rep. 2015;13(6):1125–1136. doi:10.1016/j.celrep.2015.09.082.
   PubMed Web of Science ®Google Scholar
• Woyciechowski S, Hofmann M, Pircher H. α4 β1 integrin promotes accumulation of tissue-resident memory CD8+ T cells in salivary glands . Eur J Immunol. 2017;47(2):244–250. doi:10.1002/eji.201646722.
   PubMed Web of Science ®Google Scholar
• Persson EK, Uronen-Hansson H, Semmrich M, et al. IRF4 transcription-factor-dependent CD103(+)CD11b(+) dendritic cells drive mucosal T helper 17 cell differentiation. Immunity. 2013;38(5):958–969. doi:10.1016/j.immuni.2013.03.009.
   PubMed Web of Science ®Google Scholar
• Gao Y, Nish SA, Jiang R, et al. Control of T helper 2 responses by transcription factor IRF4-dependent dendritic cells. Immunity. 2013;39(4):722–732. doi:10.1016/j.immuni.2013.08.028.
   PubMed Web of Science ®Google Scholar
• Le A, Saverin M, Hand AR. Distribution of dendritic cells in normal human salivary glands. Acta Histochem Cytochem. 2011;44(4):165–173. doi:10.1267/ahc.11010.
   PubMed Web of Science ®Google Scholar
• Schlitzer A, McGovern N, Teo P, et al. IRF4 transcription factor-dependent CD11b + dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity. 2013;38(5):970–983. doi:10.1016/j.immuni.2013.04.011.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nagashima H, Bando K, et al. Oral CD103-CD11b + classical dendritic cells present sublingual antigen and induce Foxp3+ regulatory T cells in draining lymph nodes. Mucosal Immunol. 2017;10(1):79–90. doi:10.1038/mi.2016.46.
   PubMed Web of Science ®Google Scholar
• Liu R, Tang C, Shen A, et al. IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling. Oncotarget. 2016;7(51):85079–85096. doi:10.18632/oncotarget.13196.
   PubMedGoogle Scholar
• Sfriso P, Oliviero F, Calabrese F, et al. Epithelial CXCR3-B regulates chemokines bioavailability in normal, but not in Sjogren’s syndrome, salivary glands. J Immunol. 2006;176(4):2581–2589. doi:10.4049/jimmunol.176.4.2581.
   PubMed Web of Science ®Google Scholar
• Andreasen S, Agander TK, Bjørndal K, et al. Genetic rearrangements, hotspot mutations, and microRNA expression in the progression of metastatic adenoid cystic carcinoma of the salivary gland. Oncotarget. 2018;9(28):19675–19687. doi:10.18632/oncotarget.24800.
   PubMedGoogle Scholar
• Sowa P, Goroszkiewicz K, Szydelko J, et al. A Review of Selected Factors of Salivary Gland Tumour Formation and Malignant Transformation. Biomed Res Int. 2018;2018:2897827. doi:10.1155/2018/2897827.
   PubMed Web of Science ®Google Scholar
• Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L. Major and minor salivary gland tumors. Crit Rev Oncol Hematol. 2010;74(2):134–148. doi:10.1016/j.critrevonc.2009.10.004.
   PubMed Web of Science ®Google Scholar
• Licitra L, Grandi C, Prott FJ, Schornagel JH, Bruzzi P, Molinari R. Major and minor salivary glands tumours. Crit Rev Oncol Hematol. 2003;45(2):215–225. doi:10.1016/s1040-8428(02)00005-7.
   PubMed Web of Science ®Google Scholar
• Vigili MG, Sciarretta F, Marzetti A, Marzetti F. The recurrent multifocal pleomorphic adenoma. Acta Otorhinolaryngol Ital. 1993;13(1):31–42.
   PubMedGoogle Scholar
• Kuzenko YV, Romanuk AM, Dyachenko OO, Hudymenko O. Pathogenesis of Warthin’s tumors. Interv Med Appl Sci. 2016;8(2):41–48. doi:10.1556/1646.8.2016.2.2.
   PubMedGoogle Scholar
• Capodiferro S, Ingravallo G, Limongelli L, et al. Intra-cystic (in situ) mucoepidermoid carcinoma: a clinico-pathological study of 14 cases. J Clin Med. 2020;9(4)doi:10.3390/jcm9041157.
   Web of Science ®Google Scholar
• Ghosh-Laskar S, Murthy V, Wadasadawala T, et al. Mucoepidermoid carcinoma of the parotid gland: factors affecting outcome. Head Neck. 2011;33(4):497–503. doi:10.1002/hed.21477.
   PubMed Web of Science ®Google Scholar
• Bai S, Clubwala R, Adler E, et al. Salivary mucoepidermoid carcinoma: a multi-institutional review of 76 patients. Head and Neck Pathol. 2013;7(2):105–112. doi:10.1007/s12105-012-0405-0.
   PubMedGoogle Scholar
• Godge P, Sharma S, Yadav M. Adenoid cystic carcinoma of the parotid gland. Contemp Clin Dent. 2012;3(2):223–226. doi:10.4103/0976-237X.96838.
   PubMedGoogle Scholar
• Nakaguro M, Tada Y, Faquin WC, Sadow PM, Wirth LJ, Nagao T. Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment. Cancer Cytopathol. 2020;128(10):693–703. doi:10.1002/cncy.22288.
   PubMed Web of Science ®Google Scholar
• Alame M, Cornillot E, Cacheux V, et al. The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities. Theranostics. 2020;10(10):4383–4394. doi:10.7150/thno.42986.
   PubMed Web of Science ®Google Scholar
• Ma H, Zhang M, Qin J. Probing the role of mesenchymal stem cells in salivary gland cancer on biomimetic microdevices. Integr Biol (Camb)). 2012;4(5):522–530. doi:10.1039/c2ib20026k.
   PubMed Web of Science ®Google Scholar
• Von Luttichau I, Notohamiprodjo M, Wechselberger A, et al. Human adult CD34- progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Stem Cells Dev. 2005;14(3):329–336. doi:10.1089/scd.2005.14.329.
   PubMed Web of Science ®Google Scholar
• Ghaderi A, Abtahi S. Mesenchymal stem cells: miraculous healers or dormant killers?Stem Cell Rev Rep. 2018;14(5):722–733. doi:10.1007/s12015-018-9824-y.
   PubMed Web of Science ®Google Scholar
• Razmkhah M, Abtahi S, Ghaderi A. Mesenchymal stem cells, immune cells and tumor cells crosstalk: a sinister triangle in the tumor microenvironment. Curr Stem Cell Res Ther. 2019;14(1):43–51. doi:10.2174/1574888X13666180816114809.
   PubMed Web of Science ®Google Scholar
• Lee Y, Shin JH, Longmire M, et al. CD44+ cells in head and neck squamous cell carcinoma suppress T-Cell-mediated immunity by selective constitutive and inducible expression of PD-L1. Clin Cancer Res. 2016;22(14):3571–3581. doi:10.1158/1078-0432.CCR-15-2665.
   PubMed Web of Science ®Google Scholar
• Fedele V, Melisi D. Permissive state of EMT: The role of immune cell compartment. Front Oncol. 2020;10(:587. doi:10.3389/fonc.2020.00587.
   PubMed Web of Science ®Google Scholar
• Mak MP, Tong P, Diao L, et al. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin Cancer Res. 2016;22(3):609–620. doi:10.1158/1078-0432.CCR-15-0876.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhan H. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion. Cancer Lett. 2020;468:72–81. doi:10.1016/j.canlet.2019.10.013.[InsertedFromOnline]
   PubMed Web of Science ®Google Scholar
• Spiegel JL, Jakob M, Kruizenga M, et al. Cancer stem cell markers in adenocarcinoma of the salivary glands – reliable prognostic markers?Eur Arch Otorhinolaryngol. 2021;278(7):2517–2528. doi:10.1007/s00405-020-06389-7.
   PubMed Web of Science ®Google Scholar
• Dong L, Wang YX, Li SL, et al. TGF-beta1 promotes migration and invasion of salivary adenoid cystic carcinoma. J Dent Res. 2011;90(6):804–809. doi:10.1177/0022034511401407.
   PubMed Web of Science ®Google Scholar
• Tang YL, Fan YL, Jiang J, et al. C-kit induces epithelial-mesenchymal transition and contributes to salivary adenoid cystic cancer progression. Oncotarget. 2014;5(6):1491–1501. doi:10.18632/oncotarget.1606.
   PubMedGoogle Scholar
• Tsutsumi S, Saeki H, Nakashima Y, et al. Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma. Cancer Sci. 2017;108(6):1119–1127. doi:10.1111/cas.13237.
   PubMed Web of Science ®Google Scholar
• Xu GL, Ni CF, Liang HS, et al. Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells. Gastroenterol Rep (Oxf)). 2020;8(5):390–398. doi:10.1093/gastro/goaa049.
   PubMed Web of Science ®Google Scholar
• Sisto M, Lisi S, Ribatti D. The role of the epithelial-to-mesenchymal transition (EMT) in diseases of the salivary glands. Histochem Cell Biol. 2018;150(2):133–147. doi:10.1007/s00418-018-1680-y.
   PubMed Web of Science ®Google Scholar
• Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–454. doi:10.1038/nrc822.
   PubMed Web of Science ®Google Scholar
• Georgolios A, Batistatou A, Manolopoulos L, Charalabopoulos K. Role and expression patterns of E-cadherin in head and neck squamous cell carcinoma (HNSCC). J Exp Clin Cancer Res. 2006;25(1):5–14.
   PubMed Web of Science ®Google Scholar
• Busch A, Bauer L, Wardelmann E, Rudack C, Grünewald I, Stenner M. Prognostic relevance of epithelial-mesenchymal transition and proliferation in surgically treated primary parotid gland cancer. J Clin Pathol. 2017;70(5):403–409. doi:10.1136/jclinpath-2016-203745.
   PubMed Web of Science ®Google Scholar
• Fan TF, Deng WW, Bu LL, Wu TF, Zhang WF, Sun ZJ. B7-H3 regulates migration and invasion in salivary gland adenoid cystic carcinoma via the JAK2/STAT3 signaling pathway. Am J Transl Res. 2017;9(3):1369–1380.
   PubMed Web of Science ®Google Scholar
• Langman G, Andrews CL, Weissferdt A. WT1 expression in salivary gland pleomorphic adenomas: a reliable marker of the neoplastic myoepithelium. Mod Pathol. 2011;24(2):168–174. doi:10.1038/modpathol.2010.190.
   PubMed Web of Science ®Google Scholar
• Enescu AS, Mărgăritescu CL, Crăiţoiu MM, Enescu A, Crăiţoiu Ş. The involvement of growth differentiation factor 5 (GDF5) and aggrecan in the epithelial-mesenchymal transition of salivary gland pleomorphic adenoma. Rom J Morphol Embryol. 2013;54(4):969–976.
   PubMed Web of Science ®Google Scholar
• Devi A, Yadav AB, Kamboj M, Narwal A, Kumar V, Singh V. Potential immmunohistochemical markers to characterize epithelial-mesenchymal transition in pleomorphic adenoma. J Exp Ther Oncol. 2019;13(1):1–7.
   PubMed Web of Science ®Google Scholar
• Pardis S, Zare R, Jaafari-Ashkavandi Z, Ashraf MJ, Khademi B. Twist expression in pleomorphic adenoma, adenoid cystic carcinoma and mucoepidermoid carcinoma of salivary glands. Turk Patoloji Derg. 2016;32(1):15–21. doi:10.5146/tjpath.2015.01343.
   PubMedGoogle Scholar
• Allen CT, Clavijo PE, Van Waes C, Chen Z. Anti-tumor immunity in head and neck cancer: understanding the evidence, how tumors escape and immunotherapeutic approaches. Cancers (Basel)). 2015;7(4):2397–2414. doi:10.3390/cancers7040900.
   PubMed Web of Science ®Google Scholar
• Damar M, Dinç AE, Erdem D, et al. Pretreatment neutrophil-lymphocyte ratio in salivary gland tumors is associated with malignancy. Otolaryngol Head Neck Surg. 2016;155(6):988–996. doi:10.1177/0194599816659257.
   PubMed Web of Science ®Google Scholar
• Haghshenas MR, Khademi B, Faghih Z, Ghaderi A, Erfani N. Immune regulatory cells and IL17-producing lymphocytes in patients with benign and malignant salivary gland tumors. Immunology Letters. 2015;164(2):109–116.
   PubMed Web of Science ®Google Scholar
• O’Higgins C, Ward FJ, Abu Eid R. Abu Eid R. Deciphering the role of regulatory CD4 T cells in oral and oropharyngeal cancer: a systematic review. Front Oncol. 2018;8:442. doi:10.3389/fonc.2018.00442.
   PubMed Web of Science ®Google Scholar
• Martin F, Apetoh L, Ghiringhelli F. Controversies on the role of Th17 in cancer: a TGF-β-dependent immunosuppressive activity?Trends Mol Med. 2012;18(12):742–749. doi:10.1016/j.molmed.2012.09.007.
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Crome SQ, MacDonald KG, Dai EL, Mager DL, Levings MK. Human Th1 and Th17 cells exhibit epigenetic stability at signature cytokine and transcription factor loci. J Immunol. 2011;187(11):5615–5626. doi:10.4049/jimmunol.1101058.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114(6):1141–1149. doi:10.1182/blood-2009-03-208249.
   PubMed Web of Science ®Google Scholar
• Hoechst B, Gamrekelashvili J, Manns MP, Greten TF, Korangy F. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood. 2011;117(24):6532–6541. doi:10.1182/blood-2010-11-317321.
   PubMed Web of Science ®Google Scholar
• He D, Li H, Yusuf N, et al. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol. 2010;184(5):2281–2288. doi:10.4049/jimmunol.0902574.
   PubMed Web of Science ®Google Scholar
• Huang Q, Duan L, Qian X, et al. IL-17 Promotes angiogenic factors IL-6, IL-8, and Vegf production via Stat1 in lung adenocarcinoma. Sci Rep. 2016;6:36551. doi:10.1038/srep36551.
   PubMed Web of Science ®Google Scholar
• Cosmi L, Maggi L, Santarlasci V, et al. Identification of a novel subset of human circulating memory CD4(+) T cells that produce both IL-17A and IL-4. J Allergy Clin Immunol. 2010;125(1):222–230 e1-4. doi:10.1016/j.jaci.2009.10.012.
   PubMed Web of Science ®Google Scholar
• Haghshenas MR, Khademi B, Ashraf MJ, Ghaderi A, Erfani N. Helper and cytotoxic T-cell subsets (Th1, Th2, Tc1, and Tc2) in benign and malignant salivary gland tumors. Oral Dis. 2016;22(6):566–572. doi:10.1111/odi.12496.
   PubMed Web of Science ®Google Scholar
• Sparano A, Lathers DM, Achille N, Petruzzelli GJ, Young MR. Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 2004;131(5):573–576. doi:10.1016/j.otohns.2004.03.016.
   PubMed Web of Science ®Google Scholar
• Mosconi C, de Arruda JAA, de Farias ACR, et al. Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands. Oral Oncol. 2019;88:95–101. doi:10.1016/j.oraloncology.2018.11.028.
   PubMed Web of Science ®Google Scholar
• Chang H, Kim JS, Choi YJ, et al. Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. OTT. 2017;Volume 10:2983–2992. doi:10.2147/OTT.S134589.
   Google Scholar
• Speight PM, Barrett AW. Salivary gland tumours. Oral Dis. 2002;8(5):229–240. doi:10.1034/j.1601-0825.2002.02870.x.
   PubMed Web of Science ®Google Scholar
• Linxweiler M, Kuo F, Katabi N, et al. The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype. Clin Cancer Res. 2020;26(12):2859–2870. doi:10.1158/1078-0432.CCR-19-3758.
   PubMed Web of Science ®Google Scholar
• Sridharan V, Gjini E, Liao X, et al. Immune profiling of adenoid cystic carcinoma: PD-L2 expression and associations with tumor-infiltrating lymphocytes. Cancer Immunol Res. 2016;4(8):679–687. doi:10.1158/2326-6066.CIR-16-0031.
   PubMed Web of Science ®Google Scholar
• Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity . Nature. 2015; 2015523:231–235. (7559) doi:10.1038/nature14404.
   PubMed Web of Science ®Google Scholar
• Yang Y, Ye YC, Chen Y, Zhao JL, et al. Crosstalk between hepatic tumor cells and macrophages via Wnt/β-catenin signaling promotes M2-like macrophage polarization and reinforces tumor malignant behaviors . Cell Death Dis. 2018;9(8):793. doi:10.1038/s41419-018-0818-0.
   PubMed Web of Science ®Google Scholar
• Wang R, Geng N, Zhou Y, et al. Aberrant Wnt-1/beta-catenin signaling and WIF-1 deficiency are important events which promote tumor cell invasion and metastasis in salivary gland adenoid cystic carcinoma. BME. 2015;26(s1):S2145–S53. doi:10.3233/BME-151520.
   Google Scholar
• Wend P, Fang L, Zhu Q, et al. Wnt/β-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours. Embo J. 2013;32(14):1977–1989. doi:10.1038/emboj.2013.127.
   PubMed Web of Science ®Google Scholar
• Yang Z, Li H, Wang W, et al. CCL2/CCR2 Axis promotes the progression of salivary adenoid cystic carcinoma via recruiting and reprogramming the tumor-associated macrophages. Front Oncol. 2019;9:231. doi:10.3389/fonc.2019.00231.
   PubMed Web of Science ®Google Scholar
• Sierra-Filardi E, Nieto C, Dominguez-Soto A, et al. CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2/CCR2-dependent gene expression profile. J Immunol. 2014;192(8):3858–3867. doi:10.4049/jimmunol.1302821.
   PubMed Web of Science ®Google Scholar
• Seifi S, Seyedmajidi M, Salehinejad J, Gholinia H, Aliakbarpour F. Immunohistochemical expression of CD56 and ALDH1 in common salivary gland tumors. Iran J Otorhinolaryngol. 2016;28(89):389–397.
   PubMedGoogle Scholar
• Papamichail M, Perez SA, Gritzapis AD, Baxevanis CN. Natural killer lymphocytes: biology, development, and function. Cancer Immunol Immunother. 2004;53(3):176–186. doi:10.1007/s00262-003-0478-4.
   PubMed Web of Science ®Google Scholar
• Szkaradkiewicz A, Karpiński TM, Drews M, Borejsza-Wysocki M, Majewski P, Andrzejewska E. Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-beta1) in patients with gastric cancer. J Biomed Biotechnol. 2010;2010:901564. doi:10.1155/2010/901564.
   PubMedGoogle Scholar
• Molling JW, Langius JAE, Langendijk JA, et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol. 2007;25(7):862–868. doi:10.1200/JCO.2006.08.5787.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Hong SS, Toyosawa S, Chang CK, Yagi T. Expression of major histocompatibility complex class II antigens and interleukin-1 by epithelial cells of Warthin’s tumor. Cancer. 1990;66(10):2111–2117.
   PubMed Web of Science ®Google Scholar
• Thrane PS, Halstensen TS, Haanaes HR, Brandtzaeg P. Increased epithelial expression of HLA-DQ and HLA-DP molecules in salivary glands from patients with Sjögren’s syndrome compared with obstructive sialadenitis. Clin Exp Immunol. 2008;92(2):256–262. doi:10.1111/j.1365-2249.1993.tb03389.x.
   Google Scholar
• Chin KW, Billings KR, Ishiyama A, Wang MB, Wackym PA. Characterization of lymphocyte subpopulations in Warthin’s tumor. Laryngoscope. 1995;105(9):928–933. doi:10.1288/00005537-199509000-00011.
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Nakamura Y, Nakashima T. Immunohistochemical distribution of CD9 in parotid gland tumors. Auris Nasus Larynx. 2004;31(1):49–55. doi:10.1016/j.anl.2003.09.008.
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293–12297. doi:10.1073/pnas.192461099.
   PubMed Web of Science ®Google Scholar
• Mukaigawa T, Hayashi R, Hashimoto K, Ugumori T, Hato N, Fujii S. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas. J Surg Oncol. 2016;114(1):36–43.
   PubMed Web of Science ®Google Scholar
• Krijgsman D, Roelands J, Hendrickx W, Bedognetti D, Kuppen PJK. HLA-G: A New Immune Checkpoint in Cancer?Int J Mol Sci. 2020;21(12).
   Web of Science ®Google Scholar
• Arolt C, Meyer M, Ruesseler V, et al. Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas. Cancer Immunol Immunother. 2020;69(7):1363–1373. doi:10.1007/s00262-020-02551-6.
   PubMed Web of Science ®Google Scholar
• Witte HM, Gebauer N, Lappöhn D, et al. Prognostic impact of PD-L1 expression in malignant salivary gland tumors as assessed by established scoring criteria: tumor proportion score (TPS), combined positivity score (CPS), and immune cell (IC) infiltrate. Cancers. 2020;12(4):873. doi:10.3390/cancers12040873.
   PubMed Web of Science ®Google Scholar
• Harada K, Ferdous T, Ueyama Y. PD-L1 expression in malignant salivary gland tumors. BMC Cancer. 2018;18(1):156. doi:10.1186/s12885-018-4069-3.
   PubMedGoogle Scholar
• Vital D, Ikenberg K, Moch H, Rössle M, Huber GF. The expression of PD-L1 in salivary gland carcinomas. Sci Rep. 2019;9(1):12724. doi:10.1038/s41598-019-49215-9.
   PubMedGoogle Scholar
• Dine J, Gordon R, Shames Y, Kasler MK, Barton-Burke M. Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer. Asia Pac J Oncol Nurs. 2017;4(2):127–135. doi:10.4103/apjon.apjon_4_17.
   PubMed Web of Science ®Google Scholar
• Cohen RB, Delord J-P, Doi T, et al. Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study. Am J Clin Oncol. 2018;41(11):1083–1088. doi:10.1097/COC.0000000000000429.
   PubMed Web of Science ®Google Scholar
• Long L, Zhang X, Chen F, et al. The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes Cancer. 2018;9(5-6):176–189. doi:10.18632/genesandcancer.180.
   PubMedGoogle Scholar
• Mollica Poeta V, Massara M, Capucetti A, Bonecchi R. Chemokines and chemokine receptors: new targets for cancer immunotherapy. Front Immunol. 2019;10:379. doi:10.3389/fimmu.2019.00379.
   PubMed Web of Science ®Google Scholar
• Bachelerie F, Ben-Baruch A, Burkhardt AM, et al. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2014;66(1):1–79. doi:10.1124/pr.113.007724.
   PubMed Web of Science ®Google Scholar
• Uchida D, Kuribayashi N, Kinouchi M, et al. Expression and function of CXCR4 in human salivary gland cancers. Clin Exp Metastasis. 2013;30(2):133–142. doi:10.1007/s10585-012-9518-9.
   PubMed Web of Science ®Google Scholar
• Phattarataratip E, Dhanuthai K. Expression of C-X-C motif chemokine receptors 4 and 7 in salivary gland neoplasms. Arch Oral Biol. 2017;83:136–144. doi:10.1016/j.archoralbio.2017.07.012.
   PubMed Web of Science ®Google Scholar
• Klein Nulent TJW, van Es RJJ, Valstar MH, et al. High CXCR4 expression in adenoid cystic carcinoma of the head and neck is associated with increased risk of locoregional recurrence. J Clin Pathol. 2020;73(8):476–482.
   PubMed Web of Science ®Google Scholar
• Muller A, Sonkoly E, Eulert C, et al. Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy. Int J Cancer. 2006;118(9):2147–2157. doi:10.1002/ijc.21514.
   PubMed Web of Science ®Google Scholar
• Shen Z, Li T, Chen D, et al. The CCL5/CCR5 axis contributes to the perineural invasion of human salivary adenoid cystic carcinoma. Oncol Rep. 2014;31(2):800–806.
   PubMed Web of Science ®Google Scholar
• Gao T, Shen Z, Ma C, Li Y, Kang X, Sun M. The CCL5/CCR5 Chemotactic Pathway Promotes Perineural Invasion in Salivary Adenoid Cystic Carcinoma. J Oral Maxillofac Surg 2018;76(8):1708–1718. doi:10.1016/j.joms.2018.02.009.
   PubMed Web of Science ®Google Scholar
• Legler DF, Uetz-von Allmen E, Hauser MA. CCR7: roles in cancer cell dissemination, migration and metastasis formation. Int J Biochem Cell Biol. 2014;54:78–82. doi:10.1016/j.biocel.2014.07.002.
   PubMed Web of Science ®Google Scholar
• Haghshenas MR, Ashraf MJ, Khademi B, Ghaderi A, Erfani N, Razmkhah M. and chemokine receptor patterns in patients with benign and malignant salivary gland tumors: a distinct role for CCR7. Eur Cytokine Netw. 2017;28(1):27–35. doi:10.1684/ecn.2017.0388.
   PubMed Web of Science ®Google Scholar
• Ueda M, Shimada T, Goto Y, et al. Expression of CC-chemokine receptor 7 (CCR7) and CXC-chemokine receptor 4 (CXCR4) in head and neck squamous cell carcinoma. Auris, Nasus, Larynx. 2010;37(4):488–495.
   PubMed Web of Science ®Google Scholar
• Kondo T, Ito F, Nakazawa H, Horita S, Osaka Y, Toma H. High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J Urol. 2004;171(6 Pt 1):2171–2175. doi:10.1097/01.ju.0000127726.25609.87.
   PubMed Web of Science ®Google Scholar
• Mardani M, AndishehTadbir A, Khademi B, Melekzadeh M, Vaziri L. Decreased Serum Monocyte Chemoattractant Protein1 in Salivary Gland Tumor Patients. Asian Pac J Cancer Prev. 2016;17(7):3601–3604.
   PubMedGoogle Scholar
• Diegel CR, Cho KR, El-Naggar AK, Williams BO, Lindvall C. Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma. Cancer Res. 2010;70(22):9143–9152. doi:10.1158/0008-5472.CAN-10-1758.
   PubMed Web of Science ®Google Scholar
• Sakai M, Fukumoto M, Ikai K, et al. Role of the mTOR signaling pathway in salivary gland development. Febs J. 2019;286(18):3701–3717. doi:10.1111/febs.14937.
   PubMed Web of Science ®Google Scholar
• Pai SG, Carneiro BA, Mota JM, et al. Wnt/beta-catenin pathway: modulating anticancer immune response. J Hematol Oncol. 2017;10(1):101. doi:10.1186/s13045-017-0471-6.
   PubMed Web of Science ®Google Scholar
• Wang J, Chen J, Zhang K, Zhao Y, Nör JE, Wu J. TGF-β1 regulates the invasive and metastatic potential of mucoepidermoid carcinoma cells . J Oral Pathol Med. 2011;40(10):762–768. doi:10.1111/j.1600-0714.2011.01051.x.
   PubMed Web of Science ®Google Scholar
• Phuchareon J, van Zante A, Overdevest JB, McCormick F, Eisele DW, Tetsu O. Tetsu O. c-kit expression is rate-limiting for stem cell factor-mediated disease progression in adenoid cystic carcinoma of the salivary glands. Transl Oncol. 2014;7(5):537–545. doi:10.1016/j.tranon.2014.07.006.
   PubMed Web of Science ®Google Scholar
• Chen TY, Keeney MG, Chintakuntlawar AV, et al. Adenoid cystic carcinoma of the lacrimal gland is frequently characterized by MYB rearrangement. Eye (Lond)). 2017;31(5):720–725.,. doi:10.1038/eye.2016.307.
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Bowles DW, Kang H, et al. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol. 2020;31(3):412–421. doi:10.1016/j.annonc.2019.11.018.
   PubMed Web of Science ®Google Scholar
• Locati LD, Perrone F, Cortelazzi B, et al. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. Eur J Cancer. 2016;69:158–165. doi:10.1016/j.ejca.2016.09.022.
   PubMed Web of Science ®Google Scholar
• Tchekmedyian V, Sherman EJ, Dunn L, et al. Phase II study of Lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol. 2019;37(18):1529–1537. doi:10.1200/JCO.18.01859.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Tada Y, Saotome T, et al. Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol. 2019;37(2):125–134. doi:10.1200/JCO.18.00545.
   PubMed Web of Science ®Google Scholar
• Wong SJ, Karrison T, Hayes DN, et al. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016;27(2):318–323. doi:10.1093/annonc/mdv537.
   PubMed Web of Science ®Google Scholar
• Goyal G, Mehdi SA, Ganti AK. Salivary gland cancers: Biology and systemic therapy. Oncology (Williston Park). 2015;29(10):773–780.
   PubMed Web of Science ®Google Scholar
• Stenman G, Persson F, Andersson MK. Diagnostic and therapeutic implications of new molecular biomarkers in salivary gland cancers. Oral Oncol. 2014;50(8):683–690. doi:10.1016/j.oraloncology.2014.04.008.
   PubMed Web of Science ®Google Scholar
• Barani S, Khademi B, Ghaderi A. KIR2DS4, KIR2DL2, and KIR2DS4del are linked with basaloid tumors, lymph node metastasis, advanced stage and metastatic risk in head and neck squamous cell carcinoma. Exp Mol Pathol. 2020;112:104345. doi:10.1016/j.yexmp.2019.104345.
   PubMed Web of Science ®Google Scholar
• Barani S, Khademi B, Ashouri E, Ghaderi A. KIR2DS1, 2DS5, 3DS1 and KIR2DL5 are associated with the risk of head and neck squamous cell carcinoma in Iranians. Hum Immunol. 2018;79(4):218–223. doi:10.1016/j.humimm.2018.01.012.
   PubMed Web of Science ®Google Scholar
• Morales-Estevez C, De la Haba-Rodriguez J, Manzanares-Martin B, et al. KIR genes and their ligands predict the response to Anti-EGFR monoclonal antibodies in solid tumors. Front Immunol. 2016;7:561. doi:10.3389/fimmu.2016.00561.
   PubMed Web of Science ®Google Scholar
• Faden DL, Concha-Benavente F, Chakka AB, McMichael EL, Chandran U, Ferris RL. Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma. Head Neck. 2019;41(8):2591–2601.
   PubMed Web of Science ®Google Scholar
• Jie HB, Schuler PJ, Lee SC, et al. CTLA-4(+) Regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res. 2015;75(11):2200–2210. doi:10.1158/0008-5472.CAN-14-2788.
   PubMed Web of Science ®Google Scholar
• Lopez-Albaitero A, Ferris RL. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg. 2007;133(12):1277–1281. doi:10.1001/archotol.133.12.1277.
   PubMedGoogle Scholar
• Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res. 2013;19(7):1858–1872. doi:10.1158/1078-0432.CCR-12-2426.
   PubMed Web of Science ®Google Scholar
• Trivedi S, Srivastava RM, Concha-Benavente F, et al. Anti-EGFR targeted monoclonal antibody isotype influences antitumor cellular immunity in head and neck cancer patients. Clin Cancer Res. 2016;22(21):5229–5237. doi:10.1158/1078-0432.CCR-15-2971.
   PubMed Web of Science ®Google Scholar
• Lujan B, Hakim S, Moyano S, et al. Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. Br J Cancer. 2010;103(4):510–516.
   PubMed Web of Science ®Google Scholar
• Lee JH, Jeong JH, Kim TH, et al. Induction of squamous cell carcinoma after MAP3K8 overexpression in murine salivry gland epithelial cells. Head Neck. 2019;41(4):924–929. doi:10.1002/hed.25411.
   PubMed Web of Science ®Google Scholar
• Huang Y, Yu T, Fu X, et al. EGFR inhibition prevents in vitro tumor growth of salivary adenoid cystic carcinoma. BMC Cell Biol. 2013;14:13. doi:10.1186/1471-2121-14-13.
   PubMedGoogle Scholar
• Kawahara K, Hiraki A, Yoshida R, et al. Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report. Mol Clin Oncol. 2017;6(6):886–892. doi:10.3892/mco.2017.1226.
   PubMed Web of Science ®Google Scholar
• Lai J-I, Reddy AK, Newberg JY, Montesion M, Chang PM-H. High-grade salivary gland ductal carcinoma with unusual EGFR amplification responsive to Afatinib. JCO Precision Oncology. 2019;(3):1–5.
   PubMedGoogle Scholar
• Locati LD, Bossi P, Perrone F, et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol. 2019;45(7):574–118. doi:10.1016/j.oraloncology.2008.07.010.
   Google Scholar
• Jakob JA, Kies MS, Glisson BS, et al. Phase II study of Gefitinib in patients with advanced salivary gland cancers. Head Neck. 2015;37(5):644–649. doi:10.1002/hed.23647.
   PubMed Web of Science ®Google Scholar
• Parag-Sharma K, Tasoulas J, Musicant AM, et al. Synergistic efficacy of combined EGFR and HDAC inhibitors overcomes tolerance to EGFR monotherapy in salivary mucoepidermoid carcinoma. Oral Oncol. 2021;115:105166. doi:10.1016/j.oraloncology.2020.105166.
   PubMed Web of Science ®Google Scholar
• Melnick M, Deluca KA, Sedghizadeh PP, Jaskoll T. Cytomegalovirus-induced salivary gland pathology: AREG, FGF8, TNF-α, and IL-6 signal dysregulation and neoplasia. Exp Mol Pathol. 2013;94(2):386–397. doi:10.1016/j.yexmp.2013.01.005.
   PubMed Web of Science ®Google Scholar
• Melnick M, Sedghizadeh PP, Allen CM, Jaskoll T. Human cytomegalovirus and mucoepidermoid carcinoma of salivary glands: cell-specic localization of active viral and oncogenic signaling proteins is confirmatory of a causal relationship. Exp Mol Pathol. 2012;92(1):118–125. doi:10.1016/j.yexmp.2011.10.011.
   PubMed Web of Science ®Google Scholar
• Braicu C, Buse M, Busuioc C, et al. A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers (Basel)). 2019;11(10)doi:10.3390/cancers11101618.
   Web of Science ®Google Scholar
• Ahn MY, Ahn JW, Kim HS, Lee J, Yoon JH. Apicidin inhibits cell growth by downregulating IGF-1R in salivary mucoepidermoid carcinoma cells. Oncol Rep. 2015;33(4):1899–1907. doi:10.3892/or.2015.3776.
   PubMed Web of Science ®Google Scholar
• Rodriguez CP, Wu QV, Voutsinas J, et al. A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. Clin Cancer Rese. 2020;26(4):837–845. doi:10.1158/1078-0432.CCR-19-2214.
   PubMed Web of Science ®Google Scholar